Overview

Efficacy of Belatacept in Reducing DSA

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).

Phase:

Phase 4

Details

Lead Sponsor:

East Carolina University

Treatments:

Abatacept